Hoth Therapeutics, Inc.
HOTH · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | -0.09 | -0.02 |
| FCF Yield | -15.39% | -2,190.55% | -37.18% | -26.90% |
| EV / EBITDA | -2.92 | 3.21 | 0.65 | 0.90 |
| Quality | ||||
| ROIC | -22.53% | -30.05% | -34.49% | -28.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.61 | 1.08 | 0.80 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 14.89% | -37.48% | -24.07% | -2.69% |
| Safety | ||||
| Net Debt / EBITDA | 4.09 | 3.25 | 2.94 | 3.75 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,702.91 | 0.00 | 0.00 |